Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed Feb 20, 2024 · 10-Q · 51 days after period end · 0001493152-24-007191
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$584.38K | -$485.42K | -$799.98K | -$403.64K |
| EPS Diluted | -$1,559.55 | -$0.53 | -$0.02 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 20, 2024 · 51 d after period end
